Curated News
By: NewsRamp Editorial Staff
December 20, 2024

Cognition Therapeutics Drug Shows Encouraging Results in Phase 2 Trial

Reddit Discuss on RedditDiscuss on LinkedIn LinkedInDiscuss on Substack SubstackDiscuss on Telegram Telegram
Source News Release

TLDR

  • Cognition Therapeutics Inc. (NASDAQ: CGTX) announced positive topline results of its exploratory phase 2 SHIMMER study for CT1812, its experimental orally delivered small molecule oligomer antagonist to treat dementia with Lewy bodies.
  • The phase 2 SHIMMER study enrolled 130 adults who were randomized to receive either placebo or one of two oral once-daily doses of CT1812 (100 mg or 300 mg) for six months. Participants were assessed using the Montreal Cognitive Assessment (MoCA) and Cognitive Drug Research (CDR) Battery, and other measures.
  • The study met its primary endpoint of safety and tolerability, with data showing that DLB patients treated with CT1812 for six months experienced improvement in behavioral, functional, cognitive, and movement measures compared to the placebo. This could potentially make the world a better place by providing hope to those suffering from DLB.
  • The SHINE study results showed a 95% slowing of cognitive decline in individuals with mild-to-moderate Alzheimer’s disease, demonstrating the broad neurologic and neuroprotective activity of CT1812.

Impact - Why it Matters

This news matters as it highlights a potential breakthrough in the treatment of dementia with Lewy bodies, a progressive form of dementia impacting about 1.4 million people in the U.S. With the promising results of CT1812, there is hope for a once-daily pill that can treat these devastating neurodegenerative conditions, which currently have few therapeutic options.

Summary

Cognition Therapeutics Inc. (NASDAQ: CGTX) announced positive topline results of its exploratory phase 2 SHIMMER study for CT1812, its experimental orally delivered small molecule oligomer antagonist to treat dementia with Lewy bodies. The trial demonstrated strong therapeutic responses across behavioral, functional, cognitive and movement measures in patients with DLB. The study met its primary endpoint of safety and tolerability, with data showing that DLB patients treated with CT1812 for six months experienced improvement in behavioral, functional, cognitive and movement measures compared to the placebo. Cognition plans to present detailed data at the International Lewy Body Dementia Conference in January 2025.

Source Statement

This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Cognition Therapeutics Drug Shows Encouraging Results in Phase 2 Trial

blockchain registration record for the source press release.